2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate

Product Details

CAS No:376608-65-0

MF:C10H19NO4.C4H6O6

Appearance:white or off-white crystalline powder

Specification:98.5%

UN number:-

Package:1/5/10/25kgs/drum

Supply Capacity:Tons

Synonyms:2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid;2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate;Ticagrelor InterMediate 2;2-((3aR,4R,6R,6aR)-6-Amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid;2-[[(3aR, 4S, 6R, 6aS)6-aMinotetrahydro-2,2-diMethyl-4-H-cyclopenta-1,3-dioxol-4-yl]oxy]-(2R,3R)-2,3-dihydroxybutanedioate ethanol;2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tat;2-(((3aR,4S,6R,6aS)-6-Amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol (2R,3R,4S,5R)-2,3,4,5-tetrahydroxyhexanedioate;2-[[3aR,4s,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol-L-tartrate; 2-(((3aR,4S,6R,6aS)-6-Amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol (2R,3R)-2,3-dihydroxysuccinate; 2-(((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta(d)(1,3)dioxol-4-yl)oxy)ethanol (2R,3R)-2,3-dihydroxysuccinate; 2-{[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy}ethanol (2R,3R)-2,3-dihydroxysuccinate; RefChem:446826; 690-047-9; 376608-65-0; 2-[[(3aR,4S,6R,6aS)-6-aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate; MFCD22200635; (2R,3R)-2,3-dihydroxybutanedioic acid; 2-{[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]oxy}ethan-1-ol; 2-[[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol;(2R,3R)-2,3-dihydroxybutanedioic acid; 2-((3aR,4S,6R,6aS)-6-Amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid; 2-(((3aR,4S,6R,6aS)-6-Amino-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethan-1-ol (2R,3R)-2,3-dihydroxysuccinate; Ticagrelor Impurity 41; 2-((3AR,4S,6R,6AS)-6-AMINO-2,2-DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL-4-YLOXY)ETHANOL L-TARTARIC ACID; BN6527PBL3; SCHEMBL29530882; XEYNXCGNMKWIDO-ABGQOWMBSA-N; CS-M1880; AKOS022171443; DS-3969; 2-{[(3AR,4S,6R,6AS)-6-AMINO-2,2-DIMETHYL-TETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL-4-YL]OXY}ETHANOL; L(+)-TARTARIC ACID; AC-27493; SY028121; H11357; EN300-7424391; F362149; (2R,3R)-2,3-dihydroxybutanedioic acid 2-{[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]oxy}ethan-1-ol; 2-(((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol L-tartaric acid salt; 2-(((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol(2R,3R)-2,3-dihydroxysuccinate; 2-[[(3aR,4S,6R,6aS)-6-Amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol L-Tartrate; 2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol (+)-tartaric acid; Ethanol, 2-[[(3aR,4S,6R,6aS)-6-aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt)

Product application:2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate,376608-65-0,Ticagrelor intermediate 1,Ticagrelor cyclopentane core,Ticagrelor cyclopentane amine L-tartrate,Ticagrelor chiral intermediate,P2Y12 receptor antagonist core,Antithrombotic drug intermediate,Chiral cyclopentyl building block,Carbocyclic nucleoside intermediate,Fine pharmaceutical intermediate,High enantiomeric purity intermediate,High purity Ticagrelor intermediate 1 99.5%,CAS 376608-65-0 supplier,Ticagrelor intermediate manufacturer China,Suzhou Health Chemicals specialty chemicals,Ticagrelor cyclopentane tartrate wholesale bulk export

 

2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate serves as an indispensable, ultra-pure multi-chiral carbocyclic nucleoside mimetic intermediate, benchmark cardiovascular active pharmaceutical ingredient (API) core building block, and versatile fine asymmetric synthon extensively utilized across modern antiplatelet drug manufacturing, oral antithrombotic agent commercial synthesis, novel P2Y12 receptor antagonist development, and fine medicinal chemistry sectors. In cardiovascular pharmacology and process development chemistry, universally designated as Ticagrelor Intermediate 1 or Ticagrelor Cyclopentane Tartrate, it functions as the foundational raw material for the commercial total synthesis of blockbuster oral antiplatelet therapeutics, most notably ticagrelor; its molecular architecture incorporates a rigid cyclopentane ring containing four contiguous stereogenic centers, protected by a cyclic isopropylidene ketal motif, and functionalized with a primary hydroxyethyl ether arm alongside an asymmetric primary amine salt; stoichiometric resolution with natural L-tartaric acid secures exceptional crystalline stereochemical purity exceeding 99.5% enantiomeric excess, purging trace diastereomers while passivating the reactive primary amine against oxidative degradation during prolonged storage; during downstream coupling with dichlorotriazolopyrimidine core precursors, it undergoes smooth, highly regioselective and stereospecific nucleophilic aromatic substitution to install the intact carbocyclic scaffold, creating optimal spatial alignment against the platelet purinergic P2Y12 receptor binding pocket to enable rapid, direct, and reversibly active antiplatelet efficacy without metabolic activation; this molecular configuration avoids patient-to-patient metabolic variability, providing predictable clinical antithrombotic control. In synthetic medicinal chemistry and nucleoside analogue drug discovery, it represents a foundational chiral building block for incorporating rigid, poly-hydroxylated cyclopentyl scaffolds into novel antiviral candidates, antineoplastic agents, and immunomodulatory therapeutics. Furthermore, in asymmetric catalysis ligand engineering and specialized bio-conjugate probes, chemical systems engineered from 2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate deliver exceptional stereochemical fidelity, reliable coupling efficiency, and broad multi-industry performance.